Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReSPECT study of rezafungin versus standard antimicrobial prophylaxis after allogeneic blood and marrow transplantation
2024-514471-18-00Phase 3Completed
- Sponsor
- Mundipharma
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of fosdenopterin, fluconazole, posaconazole and trimethoprim + sulfamethoxazole in invasive mycoses (2 arms), sponsored by Mundipharma. Primary endpoint: Fungal-free survival at Day 90. Started Jun 2024; status: completed.
02
Drugs
fosdenopterinfluconazoleposaconazoletrimethoprim + sulfamethoxazole
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on 2024-514471-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514471-18-00.